货号：T2922

储存条件：粉末-20°C可保存3年；液体-80°C可保存12月。

产品描述

Doxorubicin is a widely-used cancer chemotherapy active against a range of cancers including solid tumors, leukemias, and lymphomas. Doxorubicin can bind to topoisomerase II, inhibit DNA and RNA synthesis, as well as produce single stranded DNA breakage and membrane damage. Treatment with 345nM doxorubicin can activate the ATM signaling pathway, shown as the increased pATM-s1981 (at 2-24h post treatment), pNBS1-s343 (at 8-24h), pCHK2-T68 (at 4-24h), pCHK1-s296 (8-24h) in MCF-7 cells, and subsequently up-regulated endogenous Cyclin G2 and its subcellular localization in both MCF10a and MCF7 cells can be observed after treatment with 345nM doxorubicin for 16h or 24h, and potent DSB-induced G1- and G2-phase checkpoint arrest at 24h. Several signaling pathway, including AKT, PI3K, calcineurin, p38 and JNK has been proved to be responsible for doxorubicin toxicity, and p53, p21 and G2/M cell cycle arrest have been shown involved in doxorubicin-induced ROS generation and apoptosis. The autophagy induced by doxorubicin was shown to contributed to doxorubicin cardiotoxicity via decreasing GATA-4 protein expression.

产品信息